新医改形势下医院物价管理工作的问题与对策

针对新医改对医院物价管理工作的新要求,从再造新项目申报流程、完善信息系统功能、应对政策调整、加强与上级和同行的交流沟通等4个方面进行探讨,以拓展医院物价管理工作,提升物价管理水平.     

《中国心血管杂志》2007—2011年引文分析

目的分析《中国心血管杂志》2007—2011年刊载论文的引文情况,评价该杂志作者吸收和利用科技文献的规律和特征。方法利用中国知识资源总库(China national knowledge internet,CNKI)对《中国心血管杂志》2007—2011年所载论文进行检索,应用文献计量学和引文分析法,对所载论文引文量、引文语种、引文年代分布和自引率等进行分析,并计算文献的半衰期和普赖斯指数。结果该刊2007—2011年共刊载论文721篇,附有引文的论文628篇,引文率为87.10%;总引文条数6601条,篇均引文量为9.16条。该刊引文语种以英文为主,引文数占引文总数的80.97%(5345/6601),中文引文数占18.95%(1251/6601),其他语种占0.08%(5/6601)。2007—2011年该刊作者自引文献54条,自引率为0.82%;期刊自引108条,期刊自引率为1.64%。该刊引文文献的半衰期为4.20年,普赖斯指数为46.22%。结论该刊作者引用的文献范围广泛,引文时效性较好,内容较新颖,该刊具有较高的学术参考价值。     

湖南中医药大学近6年科研论文统计分析——基于WEB OF SCIENCE

运用SCI扩展版数据库数据,检索分析湖南中医药大学2008～2013年师生发表论文被SCI—E收录情况、被引用情况、科研动态,并利用洛特卡定律、普赖斯定律对湖南中医药大学的学术水平、学科领域和发展潜力进行了全面分析。     

Interferon protects neurons in culture infected with vesicular stomatitis and herpes simplex viruses

The protective effect of crude rat interferon against infection by vesicular stomatitis virus (VSV) and herpes simplex virus (HSV) was assessed in two culture systems: the PC12 cell line and dissociated rat neurons derived from the superior cervical ganglion (SCG). Interferon was induced in rat embryo cells by inactivated Newcastle disease virus, and its effect was assessed by reduction of viral yields and prevention of viral cytopathology. Interferon protected PC12 cells, both in the presence and absence of nerve growth factor (NGF), against infection by both viruses, although at differing concentrations: protection against VSV was noted at approximately a 10-fold lower interferon concentration than that required to inhibit HSV infection. Dissociated SCG neurons were also protected, but higher interferon concentrations were required. These results demonstrate that the antiviral state can be established in neurons in response to interferon.     

药品消费特殊性及其经济测量指标的辨证探讨

药品的特殊性不仅表现在其产品特性与消费模式上，更反映在社会个体与群体对健康与经济的权衡上。要深刻认识到药品消费经济测量指标的内在局限性。对药品市场实施管制重要的是提供改进效率的激励机制，而不是给予计划性的刚性约束。     

药品费用过高的原因分析与控制策略研究

药品费用的过度上涨是医药各方利用药品的二重性、委托代理消费、信息不对称等经济学特征在不合理的政策设计和制度安排所预留出的较大空间内全面互动的结果。对药品费用的控制主要从完善医院补偿机制、调整药品生产经营结构、规范药品流通秩序和行为及改革价格管理办法四个方面入手     

The diagnostic value of urinary enzyme measurements in hypertension

N-Acetyl-beta-D-glucosaminidase (NAG), beta-D-galactosidase, alkaline phosphatase (ALP) and leucine aminopeptidase (LAP) were assayed in the urine of 100 normal and 112 hypertensive subjects. Age-related urinary activities for these enzymes in the normotensive control subjects are presented. A new procedure for the assay of urinary ALP using 2-methoxy-4-(2'-nitrovinyl)phenyl (MNP) phosphate is described. Thirty-five of the hypertensive patients were considered to have primary renal disease. The urinary activity of NAG was increased in 27 (77%) of these patients and the detection of primary renal disease was not enhanced by measurements of the other urinary enzymes. Testing the urine both for NAG activity and protein, led to the detection of 91% of these patients. The assay procedures described are simple to perform and can be carried out in outpatient clinics. The measurement of urinary NAG activity is a cheap and reliable method for detecting renal disease in hypertensive patients but maximum diagnostic yield is achieved when proteinuria is determined as well.     

Price cuts and drug spending in South Korea: The case of antihyperlipidemic agents

Objective

To identify the effect of price control policies on drug expenditure in South Korea.

Methods

We retrospectively examined the effects of price-reduction policies on drug expenditures, in particular regarding anti-hyperlipidemic drugs. The National Health Insurance claims data for a 60-month period between 2006 and 2010 were analysed. A segmented regression analysis was conducted with three intervention variables: July 2008, April 2009, and January 2010.

Results

Despite three rounds of price cuts, monthly drug expenditures increased by KRW 599.67 million (USD 523,726) after the third intervention (p = 0.0781). The trend in volume increased consistently, but not significantly. The unit prices showed a steady downward trend over time, but rebounded after the third price cut. The number of patients with hyperlipidemia more than doubled to 3729 (p = 0.0801) per month after the entry of generics for atorvastatin in July 2008.

Conclusion

Extensive price controls did not effectively suppress the growth of pharmaceutical expenditures. The increased number of patients, attributable to the newly launched generic drug atorvastatin, and the increased use of expensive drugs were major factors affecting the increase in drug spending. Policies that regulate both drug prices and utilisation, and that reduce financial burdens via enhanced use of generics need to be introduced.